Publication

Article

Oncology & Biotech News

April 2015
Volume9
Issue 4

A Community in Unity

Author(s):

The Emperor of All Maladies documentary did a great job of capturing the innovative genius of mankind and the heroism of both oncologists and the patients who participated in their research.

OncLive Chairman,

Mike Hennessy

The Emperor of All Maladies

documentary did a great job of capturing the innovative genius of mankind and the heroism of both oncologists and the patients who participated in their research. There has certainly been a miraculous evolution in cancer care, from nearly uniform hopelessness to genetically targeted treatments that in some cases, eradicate the disease.

The film was not just inspirational for the story it told, but also for the reaction it generated in the oncology community. Each of the 3 nights it aired, social media lit up with enthusiastic tweets from patients, caregivers, family members, and even those who were learning the story of oncology for the first time. Several oncologists even tweeted that it felt as though they were viewing the film together with their colleagues in their living room.

genetics

epigenetics

precision medicine

collaboration

team science

multidisciplinary

It is this communal effort, this unified front in the oncology community, that will lay the foundation to forge continued advancement in cancer care. Keywords in the next chapter in oncology will not only be , , and , but also , , and .

OncLive

Oncology & Biotech News

OncLive Peer Exchange

War on Cancer

Cancers

Indeed, the motto of , the network that houses is “Bringing the Oncology Community Together.” We understand the significance of collaboration and promote interaction through our affiliate’s scientific meetings (GoToPER.com), our panels (onclive.com/peer-exchange), and several other platforms. Progress in the , or more appropriately, , requires a unified effort among caregivers, patients, researchers, industry, regulators, and donors.

The Emperor of All Maladies

Emperor

Fortunately, what experience has demonstrated is that we are “a community in unity.” Now, we must sustain this spirit to evolve beyond the history that was so eloquently captured in the film. I have full faith in our limitless capacity to do just that. As author Siddhartha Mukherjee, MD, PhD, concluded in the film’s final words, “If the cancer cell is evolving, then so are we.”

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.